Sign in

KRMD on Nasdaq

KORU Medical Systems, Inc.

KORU Medical Systems, Inc. is an American surgical and medical instruments and apparatus company.1 It is headquartered in Mahwah, New Jersey.1 Its shares trade on Nasdaq under the symbol KRMD.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Brainsway Ltd., SS Innovations International, Inc. or INTERPACE BIOSCIENCES, INC., or pick any stock.

  • TickerKRMD on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersMahwah, New Jersey1
  • Incorporated inDE2
  • Business address100 Corporate Drive, Mahwah, Nj 074302
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Increasing diagnoses of Primary Immunodeficiency Diseases (PIDD) , which frequently require immunoglobulin (Ig) treatment.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

62.3%Gross margin4
-7.2%Operating margin4
-6.4%Net margin4
22.2%Revenue growth, 20254
-15.5%Return on equity4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Regions

United States brought in 74% of the revenue KORU Medical Systems, Inc. broke down this way in fiscal 2025.

  1. United States$30.2M474%up 10% from 2024
  2. Outside the United States$10.9M426%up 77% from 2024
Regions by year
Regions20242025
United States$27.5M$30.2M
Outside the United States$6.1M$10.9M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue36¢$15.5M
  • Research and development10¢$4.4M
  • Selling, general and admin54¢$23.4M
  • Income tax0¢$21.9K

Out of $41.1M in revenue.4 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Kept or used elsewhere100¢$462.4K

Out of $462.4K of cash from operations.4

Financial statements

Revenue567894$41.1M in 2025+78% since 2019
0$20.0M$40.0M$60.0M2019: $23.2M$23.2M20192020: $24.2M$24.2M2020+4%2021: $23.5M$23.5M2021−3%2022: $27.9M$27.9M2022+19%2023: $28.5M$28.5M2023+2%2024: $33.6M$33.6M2024+18%2025: $41.1M$41.1M2025+22%
Gross profit567894$25.6M in 2025+72% since 2019
0$10.0M$20.0M$30.0M2019: $14.9M$14.9M20192020: $14.9M$14.9M2020+1%2021: $13.8M$13.8M2021−8%2022: $15.4M$15.4M2022+12%2023: $16.7M$16.7M2023+9%2024: $21.3M$21.3M2024+28%2025: $25.6M$25.6M2025+20%
Operating income567894-$3.0M in 2025
-$15.0M-$10.0M-$5.0M0$5.0M2019: $585.7K$585.7K20192020: -$1.3M-$1.3M20202021: -$7.0M-$7.0M2021+460%2022: -$10.8M-$10.8M2022+53%2023: -$10.3M-$10.3M2023−5%2024: -$6.4M-$6.4M2024−37%2025: -$3.0M-$3.0M2025−54%
Net income567894-$2.6M in 2025
-$15.0M-$10.0M-$5.0M0$5.0M2019: $564.3K$564.3K20192020: -$1.2M-$1.2M20202021: -$4.6M-$4.6M2021+276%2022: -$8.7M-$8.7M2022+90%2023: -$13.7M-$13.7M2023+59%2024: -$6.1M-$6.1M2024−56%2025: -$2.6M-$2.6M2025−57%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
NET REVENUES$41.1M$33.6M
Cost of goods sold$15.5M$12.3M
Gross Profit$25.6M$21.3M
Selling, general and administrative$23.4M$21.6M
Research and development$4.4M$5.3M
Depreciation and amortization$810.5K$888.5K
Total Operating Expenses$28.6M$27.8M
Net Operating Loss-$3.0M-$6.4M
Income/(loss) on foreign currency exchange$53.1K-$46.0K
Other income/(expense)$9.9K-$16.2K
Interest income, net$293.4K$444.6K
TOTAL OTHER INCOME$356.4K$382.5K
LOSS BEFORE TAXES-$2.6M-$6.1M
Income tax expense-$21.9K-$2.9K
NET LOSS-$2.6M-$6.1M
Basic-$0.06-$0.13
Diluted-$0.06-$0.13
Basic46.2M shares45.8M shares
Diluted46.2M shares45.8M shares

Compare KORU Medical Systems, Inc. with another company

Corporate structure

KORU Medical Systems, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of KORU Medical Systems, Inc.

  • KORU Medical Systems, Inc. Mahwah, New Jersey

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What KORU Medical Systems, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$8.5M4 Dec 31, 2025$7.8M4 Dec 31, 2024+10.0%
Accumulated depreciation$4.1M4 Dec 31, 2025$3.5M4 Dec 31, 2024+17.1%
Property and equipment, net$4.5M4 Dec 31, 2025$4.3M4 Dec 31, 2024+4.2%
Operating-lease assets (leased space)$3.0M4 Dec 31, 2025$3.0M4 Dec 31, 2024−0.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$8.9M4 Dec 31, 2025$9.6M4 Dec 31, 2024−7.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Accumulated amortization$527.9K4 Dec 31, 2025$458.5K4 Dec 31, 2024+15.1%
Finite-lived intangibles, net$684.8K4 Dec 31, 2025$730.3K4 Dec 31, 2024−6.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$3.7M4 Dec 31, 2025$2.8M4 Dec 31, 2024+31.2%
Finished goods$2.9M4 Dec 31, 2025$2.0M4 Dec 31, 2024+49.0%

Properties, in its own words

We currently rent 43,975 square feet of a building located at 100 Corporate Drive, Mahwah, New Jersey with the lease having commenced on March 1, 2022 and expiring August 31, 2032. This facility is used as our headquarters and for our in-house manufacturing operations.

Item 2 of the 10-K filed Mar 12, 2026.3

Leadership

Who has led KORU Medical Systems, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Andrew I. Sealfon2013–2016
  2. Daniel S. Goldberger2018–2019
  3. Donald B. Pettigrew2020
  4. Linda M. Tharby2021–2026
  5. Adam R. Kalbermatten2026–now

Chair

  1. Andrew I. Sealfon2011
  2. Daniel S. Goldberger2018–2019

President

  1. Andrew I. Sealfon2013
  2. Linda M. Tharby2021–2026
  3. Adam R. Kalbermatten2026–now

Chief financial officer

  1. Michael Richard Boscher2012–2014
  2. Karen Fisher2015–2020

Chief operating officer

  1. Manuel A. Marques2018–2021
  2. Christopher Pazdan2024–now
2010201520202025
Board members and other officers (24)

Former names

  • REPRO MED SYSTEMS INCJul 12, 1996 to Jun 3, 20222

Timeline

  1. Aug 14, 20268-K Bylaws or fiscal year changed47
  2. Aug 5, 20268-K Results of operations48
  3. Jul 2, 2026New chief executive Adam R. Kalbermatten becomes CEO12
  4. Jun 30, 20268-K Entered a material agreement49
  5. May 21, 20268-K Shareholder vote50
  6. May 6, 20268-K Results of operations51
  7. Apr 3, 20268-K Entered a material agreement; New debt or obligation52
  8. Mar 16, 20268-K Executive or director change53
  9. Mar 12, 20268-K Results of operations54
  10. Feb 11, 20268-K Bylaws or fiscal year changed55
  11. Jan 12, 20268-K Results of operations56
  12. Nov 25, 20258-K Entered a material agreement57
  13. Nov 12, 20258-K Results of operations58
  14. Apr 14, 2021New chief executive Linda M. Tharby becomes CEO13
  15. Dec 9, 2020New chief executive Donald B. Pettigrew becomes CEO14
  16. Oct 2, 2018New chief executive Daniel S. Goldberger becomes CEO15
  17. Apr 18, 2013New chief executive Andrew I. Sealfon becomes CEO16

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.02) a share, on Nov 12, 2025.59

When it reported results

  1. Aug 5, 2026Reported quarterly or annual results48
  2. May 6, 2026Reported quarterly or annual results51
  3. Mar 12, 2026Reported quarterly or annual results54
  4. Jan 12, 2026Reported quarterly or annual results56
  5. Nov 12, 2025Reported quarterly or annual results58
  6. Aug 6, 2025Reported quarterly or annual results60
  7. May 7, 2025Reported quarterly or annual results61
  8. Mar 12, 2025Reported quarterly or annual results62

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

332 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 47 major events, 215 insider forms, 20 large holders, 30 other. The latest 20:

  1. Oct 1, 20264 FORM 4 FOR 09-30-2026 EDGAR
  2. Oct 1, 20264 FORM 4 FOR 10-01-2026 EDGAR
  3. Oct 1, 20264 FORM 4 FOR 10-01-2026 EDGAR
  4. Oct 1, 20264 FORM 4 FOR 10-01-2026 EDGAR
  5. Oct 1, 20264 FORM 4 FOR 10-01-2026 EDGAR
  6. Oct 1, 20264 FORM 4 FOR 10-01-2026 EDGAR
  7. Sep 9, 20264 FORM 4 FOR 09-08-2026 EDGAR
  8. Aug 14, 20268-K FORM 8-K CURRENT REPORT FOR 08-13-2026 EDGAR
  9. Aug 6, 20264 FORM 4 FOR 07-28-2026 EDGAR
  10. Aug 5, 202610-Q FORM 10-Q QUARTERLY REPORT FOR 06-30-2026 EDGAR
  11. Aug 5, 20268-K FORM 8-K CURRENT REPORT FOR 08-05-2026 EDGAR
  12. Aug 3, 2026144 EDGAR
  13. Jul 29, 2026SCHEDULE 13G EDGAR
  14. Jul 13, 20264/A FORM 4/A AMENDMENT NO. 1 FOR 07-01-2026 EDGAR
  15. Jul 2, 20264 FORM 4 FOR 07-01-2026 EDGAR
  16. Jul 1, 20264 FORM 4 FOR 07-01-2026 EDGAR
  17. Jul 1, 20264 FORM 4 FOR 07-01-2026 EDGAR
  18. Jul 1, 20264 FORM 4 FOR 07-01-2026 EDGAR
  19. Jul 1, 20264 FORM 4 FOR 07-01-2026 EDGAR
  20. Jul 1, 20264 FORM 4 FOR 07-01-2026 EDGAR

The 332 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

17 open-market trades by officers, directors and large owners since October 2021: 16 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 8, 2026KALBERMATTEN ADAM RChief Commercial OfficerBuy32,000$3.16$101.1KForm 4
Jun 11, 2026KALBERMATTEN ADAM RChief Commercial OfficerBuy12,500$3.94$49.3KForm 4
May 18, 2026Schiller EricChief Technology OfficerBuy5,000$3.91$19.6KForm 4
May 15, 2026Tharby Linda MChief Executive OfficerBuy1,191$3.92$4.7KForm 4
May 15, 2026Tharby Linda MChief Executive OfficerBuy1,191$1,191.00$1.4MForm 4
May 14, 2026Pazdan ChristopherChief Operating OfficerBuy5,000$3.88$19.4KForm 4
May 14, 2026Adams Thomas EdwardChief Financial OfficerBuy5,500$3.86$21.2KForm 4
Dec 13, 2023Manko Joseph M. Jr.DirectorBuy145,833$2.40$350.0KForm 4
Dec 13, 2023Manko Joseph M. Jr.DirectorSale145,833$2.40$350.0KForm 4
Aug 21, 2023Horton Capital Partners, LLC10% ownerBuy10,000$2.65$26.5KForm 4
Aug 18, 2023Tharby Linda MChief Executive OfficerBuy5,272$2.53$13.3KForm 4
Aug 18, 2023Horton Capital Partners, LLC10% ownerBuy10,000$2.54$25.4KForm 4
Aug 16, 2023CASCELLA ROBERTDirectorBuy19,000$2.61$49.6KForm 4
May 13, 2022Tharby Linda MChief Executive OfficerBuy9,897$2.20$21.8KForm 4
May 13, 2022Manko Joseph M. Jr.DirectorBuy20,000$2.15$43.0KForm 4
May 12, 2022Tharby Linda MChief Executive OfficerBuy300$2.00$600Form 4
May 12, 2022Manko Joseph M. Jr.DirectorBuy20,000$2.01$40.2KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Adam KalbermattenChief Commercial Officer$163.6K$2.6M68
2025Linda TharbyChief Executive Officer$597.0K$1.7M68
2025Thomas AdamsChief Financial Officer$337.8K$979.3K68
2024Linda TharbyChief Executive Officer$568.8K$1.3M68
2024Thomas AdamsChief Financial Officer$334.6K$565.0K68

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 85. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
First Light Asset Management, LLC3,387,902$14.2M0.9%−380,478
Topline Capital Management, LLC3,373,842$14.2M3.7%−141,069
BlackRock, Inc.2,628,352$11.0M0.0%+256,526
Vanguard Capital Management LLC1,818,121$7.6M0.0%+131,897
Geode Capital Management, LLC1,128,096$4.7M0.0%+76,888
Simcoe Capital LLC827,393$3.5M2.1%+16,146
Meros Investment Management, LP759,664$3.2M1.0%−787
Lionhunter Capital Management, LLC693,139$2.9M1.3%New
State Street Corp646,572$2.7M0.0%−2,657
Archon Capital Management LLC642,923$2.7M1.1%No change
Northern Trust Corp347,173$1.5M0.0%+24,921
Vanguard Fiduciary Trust Co326,097$1.4M0.0%+19,644
Morgan Stanley322,959$1.4M0.0%−46,067
Vanguard Portfolio Management LLC309,833$1.3M0.0%+54,378
White Pine Capital LLC284,103$1.2M0.3%−119,389
Russell Investments Group, Ltd.269,586$1.1M0.0%−153,833
Qube Research & Technologies Ltd199,939$839.7K0.0%+20,925
Albion Financial Group /ut186,374$782.8K0.0%−30,000
Renaissance Technologies LLC164,900$692.6K0.0%+119,000
Connor, Clark & Lunn Investment Management Ltd.152,944$642.4K0.0%+12,201
Charles Schwab Investment Management Inc126,710$532.2K0.0%+18,829
Squarepoint Ops LLC124,755$524.0K0.0%+111,733
HighMark Wealth Management LLC120,935$507.9K0.2%No change
Goldman Sachs Group Inc100,475$422.0K0.0%−125,281
PNC Financial Services Group, Inc.97,000$407.4K0.0%−5

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How KORU Medical Systems, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARKORU Medical Systems, Inc.1
  • CIK0000704440
  • Employer ID (EIN)13-30448803
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address100 Corporate Drive, Mahwah, NJ 074301
  • Phone845-469-20421
  • Shares outstanding46,171,902 as of Aug 5, 202611
  • Public float$119.1M as of Jun 30, 20253
  • AuditorCherry Bekaert LLP, Tampa, Florida PCAOB ID 6773
  • On EDGAR sinceJul 12, 19961
  • Filings963 in all: 4 (455), 8-K (136), 10-Q (54), 10QSB (37), 3 (30), 4/A (30), 5 (18), 10-K (17)1
    All 46 form types

    424B3 (17), NT 10-Q (16), 10KSB (12), SC 13D/A (12), SC 13G/A (12), DEF 14A (10), NT 10-K (10), UPLOAD (10), 10QSB/A (7), S-8 (7), 144 (6), CORRESP (6), PRE 14A (5), SC 13G (5), SCHEDULE 13G/A (5), 10-Q/A (4), 8-K/A (4), EFFECT (4), S-8 POS (4), 3/A (3), DEFA14A (3), 424B5 (2), 5/A (2), REGDEX (2), S-3 (2), SC 13D (2), SCHEDULE 13D/A (2), SCHEDULE 13G (2), 10-K/A (1), 10-KT (1), 10KSB/A (1), 8-A12B (1), 8-A12B/A (1), CERT (1), POS AM (1), S-1 (1), S-1/A (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Mar 12, 2026
    Quarterly report (10-Q) Aug 5, 2026
    Proxy statement (DEF 14A) Apr 9, 2026
    Latest 8-K (8-K) Aug 14, 2026

Securities registered for trading

ClassSymbolExchange
common stock, $0.01 par valueKRMDThe Nasdaq Stock Market

From the cover page of the 10-K filed Mar 12, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks KORU Medical Systems, Inc. names in Item 1A of its 10-K filed Mar 12, 2026: 51 risks under these headings, as written.3

  • Risks Related to Our Business
  • If we are unable to successfully introduce new products or fail to keep pace with advances in technology, our business, financial condition and results of operations could be adversely affected.
  • Our business depends on an adequate supply of drugs to be administered by our products.
  • The size of the markets for our products and any future products may be smaller than we estimate and may decline.
  • We sell a majority of our products through only a few distributors on whom we depend, and our financial results depend on their purchasing patterns.
  • Most of our components and raw materials, including all of our consumables subassemblies, are sourced from single suppliers. If we are unable to obtain sufficient components or raw materials on a timely basis or for a cost-effective price, or if we experience other supply difficulties, our business and results of operations may be adversely affected.
  • Interruption of our manufacturing or our contract manufacturing operations could adversely affect our business.
  • If we are unable to compete successfully in our highly competitive industry, our business and financial condition may be adversely affected.
  • Technological developments by others may disrupt our business and negatively impact our revenues.
  • If a cybersecurity incident was to occur, it could cause substantial disruption to our information systems and breaches of our security systems which could harm our business, customer relations and financial condition.
  • If we are unable to protect our patents or other proprietary rights, or if we infringe the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.
  • We need to attract and retain key employees to be competitive.
The other 40 risks
  • Recent immigration enforcement actions in the U.S. could impact our operations or the operations of our suppliers and vendors, and the ability to retain talented personnel.
  • Risks Related to Our Industry
  • Failure to obtain 510(k) clearance or PMA approval from the FDA for our new products or enhancements to our existing products may affect our ability to grow our business.
  • Healthcare policy changes and industry cost-containment measures could result in downward pricing pressure for our products and limit our sales.
  • Issues with product quality could have an adverse effect upon our business, subject us to regulatory actions, cause a loss of customer confidence in us or our products, among other negative consequences.
  • Defects or quality issues associated with our products could adversely affect the results of our operations.
  • The therapeutic efficacy of certain of our biopharma customers’ products that may utilize our device are either unproven in humans or has only been proven in limited circumstances, and we may not be able to successfully develop and sell our products in combination with our biopharma customers’ products.
  • Certain of the injectable therapies being targeted for use with our products are not approved but are in various phases of clinical development. These injectable therapies may be independently terminated by their makers prior to submission of a regulatory filing or even after regulatory approval and pharmaceutical developers may cease their efforts with us, resulting in the cessation of any revenue associated with that contract or program.
  • Our commercial success depends upon the attainment of significant market acceptance of drug product candidates to be included in our biopharma customers’ products that may utilize our device, if approved, among physicians, patients, healthcare payers or the medical community.
  • If coverage and reimbursement from third-party payors for procedures utilizing our products are inadequate, adoption of our products will be adversely affected and our revenues and prospects for profitability will suffer.
  • Most brand name injectable therapies will face future competition from generic or biosimilar therapies, which could significantly reduce their commercial viability.
  • Risks Related to Legal and Regulatory Compliance
  • We are subject to costly and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations.
  • We and the biopharmaceutical companies with whom we do novel therapies business (“our biopharma customers”) are subject to extensive regulation by governments around the world, and if these regulations are not complied with, existing and future operations may be curtailed, and we could be subject to liability.
  • Our compliance with EU MDR regulations by December 2028 will require significant investment and, if we are not in compliance by that time, we will not be able to sell our products in the EU.
  • Our failure to comply with laws and regulations relating to reimbursement of healthcare products may subject us to penalties and adversely impact our reputation, business, results of operations, financial condition and cash flows.
  • Risks Related to Economic Conditions
  • Our distribution network and other operations outside the U.S. subject us to certain risks.
  • Rising inflation increases economic uncertainty and may require us to raise prices in order to maintain our operating margins.
  • We are subject to foreign currency exchange risk.
  • A government shutdown may have a material adverse impact on our business and results of operations.
  • A downturn in global economic conditions in government-sponsored healthcare systems could adversely affect our operations.
  • Public health crises, such as the COVID-19 pandemic, have had, and could in the future have, a negative effect on our business.
  • Brexit may impact our business in the United Kingdom.
  • Risks Related to Our Financial Position
  • We may need additional funding in the future, and if we are unable to raise capital when needed, we may be forced to delay, reduce or eliminate our product development, commercial efforts, or sales efforts.
  • We are required to comply with certain financial and operating covenants under our credit facility. Failure to comply with these covenants would prevent us from drawing on our facility and, once drawn, could cause amounts borrowed to become immediately due and payable.
  • Changes in tax or labor laws or exposure to additional income tax liabilities could increase our costs and reduce our margins.
  • Changes in tariff and trade policies by the US administration, and uncertainties with respect to such policies, may have an adverse impact on our costs of goods and gross margin.
  • Our operating results and financial condition may fluctuate.
  • Future material impairments in the value of our long-lived assets could negatively affect our operating results.
  • Risks Related to Ownership of Our Common Stock
  • There may be circumstances in which the interests of our significant stockholders could be in conflict with your interests as a stockholder.
  • We do not currently intend to pay dividends on our common stock.
  • Future sales and issuances of shares of our common stock or rights to purchase our common stock, including pursuant to our equity compensation plans, could result in additional dilution of the percentage ownership of our stockholders.
  • There has been volatility in the price of shares of our common stock.
  • If we do not maintain compliance with the listing standards of the Nasdaq Capital Market, Nasdaq may delist our common stock from trading on its exchange.
  • We are a smaller reporting company and non-accelerated filer, and we cannot be certain if the reduced disclosure requirements applicable to us will make our common stock less attractive to investors.
  • The price of our common stock may be adversely affected by the future issuance and sale of shares of our common stock or other equity securities.
  • You may find it difficult to sell our common stock.
  • Actions of activist stockholders could have an adverse effect on our business.
  • General Risk Factors
  • Natural disasters, war and other events could adversely affect our suppliers and customers.
  • We are dependent on information technology systems and subject to privacy and security laws, and our systems and infrastructure face certain risks, including from cyber security breaches and data leakage.
  • We are subject to lawsuits.
  • Our insurance coverage may be inadequate to cover all the liabilities we may incur.

Legal proceedings

In the ordinary course of our business, we may be subject to various claims, pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. We are not aware of any current material pending legal proceedings to which we are a party or of which any of our properties is the subject.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68